HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
Building partnerships is key to expanding our portfolio to achieve strong sustainable growth.
We want to win late stage partnering opportunities that will exploit our strengths and infrastructure in Europe, Australia and New Zealand.
We are committed to acquire specialised innovative products from companies in Europe, the US and elsewhere who have a complementary vision to improve patients’ lives. Through our agile and flexible organisation we have the ability to deploy a single opportunity across our entire network of affiliates or maximise opportunities locally.
We are focusing on specialist products which are:
Strong partnering track record
Many ways to partner: licensing, acquisition, joint venture, flexible deal structure
a single integrated European model, 14 sites, over 1,300 people
Specialist therapy areas: gastroenterology, hepatology, cancer and supportive care
€395 million total net product sales in 2018
One Norgine approach – we think globally but act locally.
We license in or acquire products in late stage development or already approved such that either -
we own the asset outright and control all future development
we share responsibility for future development in collaboration with the licensor
We make our products such as MOVICOL®, MOVIPREP® and PLENVU®, available to patients in territories where we do not have our own sales force by finding suitable partners and utilising their local knowledge and expertise
As a private company we are able to be creative and flexible in the structure of deals